Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kelli Hammond"'
Autor:
Andrew B. Nixon, Federico Innocenti, Hanna K. Sanoff, Michael S. Lee, Dominic T. Moore, Anastasia Ivanova, Kouros Owzar, Chiara Cremolini, Alfredo Falcone, Richard M. Goldberg, Daniele Rossini, Federica Marmorino, Kelli Hammond, John C. Brady, Mark D. Starr, Ace J. Hatch, Alexander B. Sibley, Kirsten Bell Burdett, Jing Lyu, Yingmiao Liu
Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc13a6f6766962d7be65cf3e676a3ff
https://doi.org/10.1158/1535-7163.c.6542764
https://doi.org/10.1158/1535-7163.c.6542764
Autor:
Andrew B. Nixon, Federico Innocenti, Hanna K. Sanoff, Michael S. Lee, Dominic T. Moore, Anastasia Ivanova, Kouros Owzar, Chiara Cremolini, Alfredo Falcone, Richard M. Goldberg, Daniele Rossini, Federica Marmorino, Kelli Hammond, John C. Brady, Mark D. Starr, Ace J. Hatch, Alexander B. Sibley, Kirsten Bell Burdett, Jing Lyu, Yingmiao Liu
Figure S1, consort diagram. Table S1, pts characteristics. Table S2, baseline levels. Table S3, prognostic markers. Table S4, adjusted prognostic markers. Table S5, early changes. Table S6, late changes at disease progression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e03a78e049b3b467e3d8a40989bca42
https://doi.org/10.1158/1535-7163.22520767
https://doi.org/10.1158/1535-7163.22520767
Autor:
Julia C. F. Quintanilha, Kelli Hammond, Yingmiao Liu, Federica Marmorino, Beatrice Borelli, Chiara Cremolini, Andrew B. Nixon, Federico Innocenti
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(9)
Hypertension is a common toxicity induced by vascular endothelial growth factor (VEGF) pathway inhibitors. There are no validated markers of hypertension induced by these drugs.We previously discovered that cancer patients with lower plasma levels of
Autor:
Julia C. F. Quintanilha, Susan Geyer, Amy S. Etheridge, Alessandro Racioppi, Kelli Hammond, Daniel J. Crona, Carol E. Peña, Sawyer B. Jacobson, Federica Marmorino, Daniele Rossini, Chiara Cremolini, Hanna K. Sanoff, Ghassan K. Abou-Alfa, Federico Innocenti
Publikováno v:
Pharmacogenomics J
No biomarkers are available to predict toxicities induced by VEGFR TKIs. This study aimed to identify markers of toxicities induced by these drugs using a discovery-validation approach. The discovery set included 140 sorafenib-treated cancer patients
Autor:
Alfredo Falcone, Chiara Cremolini, Jing Lyu, Dominic T. Moore, Daniele Rossini, Richard M. Goldberg, Anastasia Ivanova, Yingmiao Liu, Ace J. Hatch, Alexander B. Sibley, Kelli Hammond, Andrew B. Nixon, Federica Marmorino, Federico Innocenti, Hanna K. Sanoff, Mark D. Starr, Kouros Owzar, John C. Brady, Kirsten Bell Burdett, Michael S. Lee
Publikováno v:
Molecular Cancer Therapeutics. 19:2146-2154
Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, met
Autor:
Alessandro Racioppi, Stefanie Denning, Amy S. Etheridge, Jin Wang, Susan Geyer, Julia C F Quintanilha, Kelli Hammond, Carol Peña, Daniel J. Crona, Federico Innocenti, Sawyer B. Jacobson, Ghassan K. Abou-Alfa
Publikováno v:
Journal of Clinical Oncology. 39:3030-3030
3030 Background: Diarrhea, HFS, and hypertension are common toxicities of sorafenib. No markers are validated to predict patients at risk of these toxicities. This study aimed to identify genetic predictors of sorafenib-induced toxicities. Methods: A
Autor:
Temitope O. Keku, Hanna K. Sanoff, Sushant A. Patil, Michael S. Lee, Kelli Hammond, Todd Auman, Ganiraju C. Manyam, Sara R. Selitsky, Scott Kopetz, Joel S. Parker, Federico Innocenti, Amber N. McCoy
Publikováno v:
Cancer Research. 80:A03-A03
Background: F. nucleatum is an oral anaerobe aberrantly found in up to 43% of CRCs. F. nucleatum presence is associated with additional known prognostic variables, including BRAF mutation and immune infiltration. In nonmetastatic CRC, F. nucleatum is
Autor:
James Todd Auman, Joel S. Parker, Federico Innocenti, Michael Sangmin Lee, Kelli Hammond, Sara R. Selitsky, Sushant A. Patil, Hanna K. Sanoff
Publikováno v:
Journal of Clinical Oncology. 38:196-196
196 Background: LCCC1029 was a 2:1 randomized phase II trial of 2nd-line FOLFIRI plus either regorafenib or placebo in mCRC. The addition of regorafenib improved PFS (median PFS 6.1 vs 5.3 mo, HR 0.73, 95% CI 0.53-1.01). However, the effect of somati
Autor:
Dominic T. Moore, Andrew B. Nixon, Yingmiao Liu, J. Chris Brady, Bert H. O'Neil, Kirsten Bell Burdett, Kelli Hammond, Hanna K. Sanoff, Mark D. Starr, Federico Innocenti, Ace J. Hatch, Anastasia Ivanova, Michael Sangmin Lee, Kouros Owzar
Publikováno v:
Journal of Clinical Oncology. 37:587-587
587 Background: The LCCC1029 trial demonstrated that addition of the multitargeted kinase inhibitor regorafenib (Rego) to FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts) modestly prolonged progression-free survival (PFS). In this prepla
Autor:
Bert H. O'Neil, Michael Sangmin Lee, Joel S. Parker, Federico Innocenti, Yunhan Wu, James Todd Auman, Kelli Hammond, Sara R. Selitsky, Hanna K. Sanoff
Publikováno v:
Journal of Clinical Oncology. 37:597-597
597 Background: LCCC1029 was a 2:1 randomized phase II trial of second-line FOLFIRI plus either regorafenib or placebo in mCRC that showed no statistically significant difference in PFS or OS. CMS, defined using gene expression, is prognostic for PFS